Fig. 1: Higher mTORC1/C2 activity was observed in post-transplant compared to non-transplant renal cell carcinomas.
From: Tumorigenic role of tacrolimus through mTORC1/C2 activation in post-transplant renal cell carcinomas
mTORC1/C2 activity was higher in post-transplant (post-tx) compared to non-transplant (non-tx) papillary (pRCC) and clear cell (ccRCC) renal cell carcinomas. a Haematoxylin-eosin (H&E) and IHC stainings (p-mTOR, p-S6, Rictor, PTEN) were performed. DAB was used as a chromogen with haematoxylin counterstaining. Scale bars indicate 50 μm. b Expression of mTORC1/2 markers in post-tx and non-tx RCCs. Expressions are defined as deviations upper (high expression) or lower (low expression) from the median H-score value. *p < 0.05 was considered as statistically significant, †p < 0.1. c Case distribution regarding mTORC2 activity in post-tx and non-tx ccRCCs and pRCCs. “mTORC2-high” cases were defined based on the upper deviation from the median H-score values of both p-mTOR (the active form of the catalytic subunit of mTORC1 and mTORC2) and Rictor (scaffold protein of mTORC2).
